Sagitta Biotech
0724.569.610 · rovalta.com · 25/09/2026
Sagitta Biotech
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOSagitta Biotech is a Public limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0724.569.610
- Incorporation
- 04/04/2019
- Legal form
- Public limited company
- Registered office
- Avenue Hippocrate 5 box GIGA
4000 Liège · WallonieSee on map - Contributed capital
- 1 270 000,00 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 8 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -138,7 k € | +24.8% | -184,3 k € | +39.6% | -305,2 k € | -1413% | -20,2 k € | -1082% | -1,7 k € |
| EBITDA | -319,5 k € | +8.9% | -350,8 k € | -11.8% | -313,9 k € | -1402% | -20,9 k € | -887% | -2,1 k € |
| Operating result | -353 k € | +6.9% | -379,1 k € | -15.3% | -328,8 k € | -1474% | -20,9 k € | -887% | -2,1 k € |
| Net result | -354,7 k € | +6.5% | -379,5 k € | -15.1% | -329,8 k € | -1453% | -21,2 k € | -783% | -2,4 k € |
| Balance sheet | |||||||||
| Equity | 353,4 k € | +585% | -72,9 k € | -124% | 306,6 k € | +2343% | -13,7 k € | -281% | 7,6 k € |
| Total assets | 981,7 k € | +110% | 466,7 k € | -42.8% | 815,6 k € | +5004% | 16 k € | +45.7% | 11 k € |
| Cash | 148,1 k € | +256% | 41,6 k € | -93.6% | 649,4 k € | +891022% | 72,9 € | +6237% | 1,2 € |
| Debts | 628,3 k € | +16.4% | 539,6 k € | +6.6% | 506,2 k € | +1608% | 29,6 k € | +771% | 3,4 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20253 active · 9 ended
Active mandates
Ended mandates
Other companies at this address
Avenue Hippocrate 5 4000 Liège| Company | CBE no. |
|---|---|
Apmonia Therapeutics● Active | 1026.581.583 |
ARTIALIS● Bankrupt | 0830.584.472 |
BRENUS PHARMA BELGIUM● Active | 1025.810.137 |
QUIDDITAS● Active | 0794.472.362 |
Temple OrthoBiologics● Active | 1012.358.316 |
XeroThera Europe● Active | 0697.932.717 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 15/04/2026 | 31/03/2025 | 03/04/2024 | 21/03/2023 | 19/04/2022 | 18/03/2021 |
| General meeting | 15/04/2026 | 17/02/2025 | 19/02/2024 | 20/02/2023 | 21/02/2022 | 15/02/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 8 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro modelCorrection | 31/12/2025 | 15/04/2026 | 15/04/2026 | French | |
| Micro model | 31/12/2025 | 16/02/2026 | 26/03/2026 | French | |
| Micro model | 31/12/2024 | 17/02/2025 | 31/03/2025 | French | |
| Micro model | 31/12/2023 | 19/02/2024 | 03/04/2024 | French | |
| Micro model | 31/12/2022 | 20/02/2023 | 21/03/2023 | French | |
| Micro model | 31/12/2021 | 21/02/2022 | 19/04/2022 | French | |
| Micro model | 31/12/2020 | 15/02/2021 | 18/03/2021 | French | |
| Micro model | 31/12/2019 | 17/02/2020 | 24/03/2020 | French |
Valuation
Indicative valuation
As an indication, this company is worth
between 250 k€ and 500 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20253 active · 9 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Registered office23/04/2026SIEGE SOCIAL - CAPITAL, ACTIONS
- Capital / shares01/08/2025CAPITAL, ACTIONS
- Capital / shares12/03/2025STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - DIVERS - CAPITAL, ACTIONS
- Mandates18/01/2023STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - MODIFICATION FORME JURIDIQUE - SIEGE SOCIAL - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
- Other08/04/2019RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-354,7 k €↑
- 2024Annual accounts 2024-379,5 k €↓
- 2023Annual accounts 2023-329,8 k €↓
- 2022Annual accounts 2022-21,2 k €↓
- 2021Annual accounts 2021-2,4 k €
- 04/04/2019IncorporationPublic limited company